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Background: Inhaled corticosteroids enhance airway epithelial barrier integrity. However, the mecha-
nism by which they accomplish this is unclear. Therefore, we investigated steroid-inducible genes and
signaling pathways that were involved in enhancing airway epithelial barrier integrity.
Methods: A human bronchial epithelial cell line (16HBE cells) was cultured with 106 M dexamethasone
(DEX) for 3 days to enhance epithelial barrier integrity. After measuring transepithelial electrical resis-
tance (TER) and paracellular permeability, we extracted total RNA from 16HBE cells and performed
microarray and pathway analysis. After we identiﬁed candidate genes and a canonical pathway, we
measured TER and immunostained for tight junction (TJ) and adherent junction (AJ) proteins in cells that
had been transfected with speciﬁc small interfering RNAs (siRNAs) for these genes.
Results: We identiﬁed a nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated oxidative stress
response pathway which was primarily involved in the steroid-induced enhancement of airway
epithelial barrier integrity. Transfecting cells with Nrf2 speciﬁc siRNA reduced the steroid-induced
enhancement of airway epithelial barrier integrity and the accumulation of TJ and AJ proteins at sites
of cellecell contact. Moreover, based on pathway analysis, aldehyde oxidase 1 (AOX1) was identiﬁed as a
downstream enzyme of Nrf2. Transfecting cells with AOX1-speciﬁc siRNA also reduced the steroid-
induced enhancement of airway epithelial barrier integrity.
Conclusions: Our results indicated that the Nrf2/AOX1 pathway was important for enhancing airway
epithelial barrier integrity. Because the airway epithelium of asthmatics is susceptible to reduced barrier
integrity, this pathway might be a new therapeutic target for asthma.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Asthma is a highly complex, heterogeneous disease that is
characterized by airway inﬂammation associated with T helper





rgology. Production and hosting by Elsehyperresponsiveness.1e3 Inhaled corticosteroids (ICS) have recently
been used to treat asthma to control chronic airway inﬂammation
and the associated underlying pathways involved with TH2 re-
sponses.4 Thewider use of ICS has resulted in a reduction of asthma
symptoms and airway hypersensitivity, improvements in quality of
life, and reduced mortality rates.5 However, there are a signiﬁcant
number of patients with severe asthma that is resistant to ICS
therapy,6 which suggests that there are other mechanisms under-
lying asthma in addition to chronic allergic airway inﬂammation.
It was reported that airway epithelial barrier integrity in pa-
tients with asthma was reduced as compared with that of healthy
people.7 We previously reported that steroids could enhancevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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tion of epidermal growth factor receptors (EGFR).8 EGFRs play a
major role in the growth and specialization of the airway epithe-
lium.9 EGFR expression is enhanced not only in the normal airway
epithelium but also in the injured airway epithelium of asthma
patients.10
The airway epithelial barrier is formed by intercellular binding
components including adherent junctions (AJ) and tight junctions
(TJ). An AJ is comprised of E-cadherin and associates with actin
through b-catenin. A TJ is located at the apex of an intercellular
adhesion site11 and is formed by interacting proteins such as zonula
occludens (ZO) 1e3, occludin, and claudins 1e5.12,13 In particular, a
TJ is a principle structural component for paracellular perme-
ability.14 When a TJ is disrupted, environmental factors can readily
enter the airway and cause allergic airway inﬂammation.7
Enhancing these intercellular binding components could poten-
tially lead to new treatments for asthma.
Thus, in this study, we conducted a global gene expression
analysis and attempted to identify steroid-inducible genes and
signaling pathways to determine the mechanism by which steroids
could enhance airway epithelial barrier integrity.
Methods
Cells and reagents
A differentiated SV40-transformed human bronchial epithelial
cell line (16HBE14o; hereafter referred to as 16HBE cells) was a
generous gift from Dr. D.C. Gruenert (University of California, San
Francisco, CA, USA). Dexamethasone (DEX) and ﬂuorescein
isothiocyanate-labeled dextran (FITC-dextran; 4 and 10 kDa) were
from Sigma Chemical Company (St. Louis, MO, USA).
Cell culture
16HBE cells were grown in minimum essential medium (MEM)
supplemented with 10% (v/v) fetal bovine serum (FBS) and used at
passages 10e30. 16HBE cells were seeded on Transwell inserts
(Costar, Corning, NY, USA) at a density of 1  105 cells/cm2. 16HBE
cells seeded on Transwell inserts were cultured with or without
106 M DEX for up to 3 days.
Transepithelial electrical resistance measurements
TER measurement using 16HBE cells has been established in
previous studies based on paracellular transport.15e17 These were
seeded on Transwell inserts at 1105 cells/cm2. The integrity of the
cell monolayer was evaluated by measuring transepithelial elec-
trical resistance (TER) using a Millicell-ERS system (Millipore Corp.,
Bedford, MA, USA) according to the manufacture's instruction. TER
(ohms cm2) was calculated using the equation: (TER sampleTER
blank)  surface area (cm2).18
Apparent permeability coefﬁcient
The permeability of a cell monolayer was determined by FITC-
dextran ﬂuxes across this layer. A solution that contained 4-kDa
FITC-dextran (1 mg/ml) was added to the apical compartment of
a Transwell insert. Samples (200 ml) were removed from the basal
compartments at 60 min after adding FITC-dextran and FITC-
dextran intensity was measured using a PTI ﬂuorometer set for
excitation at 492 nm and emission at 520 nm. An apparent
permeability coefﬁcient (Papp) was obtained using the equation:
Papp (cm/s) ¼ dQ/dt(V/AC 0), where dQ/dt was the permeability
rate (mg/s), C0 was the initial concentration in the upper chamber(mg/ml), V was the volume of the upper chamber (cm3), and A was
the membrane surface area (cm2).19
RNA extraction
16HBE cells were cultured for 3 days with or without DEX. Total
RNA was isolated on day 0 and day 3 of culture using a QIAGEN
RNeasy Minikit (Qiagen, Valencia, CA, USA). RNA samples were
adjusted using an Ambion WT Expression Kit (Affymetrix, Santa
Clara, CA, USA), according to the manufacturer's protocol.
Microarray analysis, pathways and network analysis
Fragmented second-cycle cDNA was labeled using a GeneChip
WT Terminal Labeling Kit (Affymetrix), according to the manufac-
turer's protocol. We conﬁrmed DNA fragmentation using an Agilent
RNA 6000 Nano Kit (Agilent Technologies, Palo Alto, CA, USA), ac-
cording to the manufacturer's protocol. Next, we used Gene Chip
HU Gene 1.0 ST Arrays (Affymetrix) for microarray analysis. An
array was hybridized using Genechip Fluidics Station 450 and a
Genechip Scanner 3000 (Affymetrix) to measure ﬂuorescence in-
tensity. The obtained gene data were subjected to statistical anal-
ysis using GeneSpring 12.5 software (Agilent Technologies UK
Limited, South Queensferry, UK). Candidate genes that were
apparently associated with enhanced barrier integrity were iden-
tiﬁed. We also used gene data to perform pathway analysis using
Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems Inc.,
Redwood City, CA, USA).
Real-time polymerase chain reaction
Real-time polymerase chain reaction (PCR) analysis was per-
formed using an Ambion Fast SYBR Green Cells-to-CT Kit (Life
Technologies, Carlsbad, CA, USA), according to the manufacturer's
protocol. Using the protocols for an Applied Biosystems 7300 Fast
Real- Time PCR system and SYBR green PCR master mix (Life
Technologies), PCR was performed in 96-well plates with dena-
turing at 95 C for 20 s, followed by 40 cycles of annealing at 95 C
for 3 s and ampliﬁcation at 60 C for 30 s. We set the initial
threshold and determined the Ct value. We evaluated the RNA level
of each sample using the comparative determination method
(⊿⊿CT method).20
The primers sequences were listed below:
BIRC3, 50-ATGCTTCTGTTGTGGCCTGAT-30 and 50-GTTAACGGA
ATTTAGACTCTGAACGA-30;
KRT6A, 50-GGCTGAGGAGCGTGAACAG-30 and 50-CCAGGAACCG
CACCTTGT-30;
AOX1, 50-CAGCGCTGATCACCGAATCT-30 and 50-GTACATGTTTAT
GATTCGCACCTTCT-30;
LOX, 50-TGAGTTTAGCCACTATGACCTGCTT-30 and 50-AAACTTGCT
TTGTGGCCTTCA-30;
NNMT, 50-AGAGGCTGGCTACACAATCGA-30 and 50-GTTGGCCA
TGGTGGAAGAATA-30;
KLK6, 50-CCTTCGGCAAAGGGAGAGTT-30 and 50-GCTGGCGGCAT-
CATAGTCA-30;
RASGRP1, 50-TCAATAAGGTTCTCGGTGAGATGA-30 and 50-TGAA
GTCGGTGCACTCTCCAT-30;
TFPI2, 50- CGATGCTTGCTGGAGGATAGA-30 and 50-CACTGGTCG
TCCACACTCACTT-30;
LCN2, 50-TGACTACTGGATCAGGACTTTTGTTC-30 and 50-CTTAA
TGTTGCCCAGCGTGAA-30;
ID2, 50-CACGTCATCGACTACATCTTGGA-30 and 50-TGGTGATGCA
GGCTGACAAT-30;
GAPDH, 50-GTCGGAGTCAACGGATTTGG-30 and 50-GGCAACAA-
TATCCACTTTACCAGAG-30
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To determine which candidate gene products might enhance
epithelial cell barrier function, we transfected 16HBE cells with
small interfering RNAs (siRNAs) of the candidate genes using Lip-
ofectamine RNAiMAX (Life Technologies). After 24 h, transfected
cells were transferred to a Transwell chamber, cultured with me-
dium that contained DEX, and assessed for cell monolayer barrier
function by measuring TER.
SiRNA used in transfection are listed below:
Stealth RNAi™ siRNA Negative Control Med GC Duplex (Life
Technologies)
NFE2L2 siRNA (Sigma): SASI_Hs01_00182394 HUMAN
NM_006164 1917 MISSION®
AOX1 siRNA(Sigma): SASI_Hs01_00221863 HUMANNM_001159
1963 MISSION®
Fluorescent immunostaining
Cell monolayers were ﬁxed with 4% paraformaldehyde at 37 C
for 60 min. Cells were then washed with PBS (Sigma), after which
3% bovine serum albumin (BSA; Sigma) was added to block non-Fig. 1. DEX treatment enhances permeability barrier formation in 16HBE cells. A. DEX eff
cultured with DEX. TER was monitored for 3 days. Results are means ± SDs (n ¼ 3); *P < 0.05
Cells were seeded on Transwell inserts and cultured with DEX for 3 days. Fluorescence in
dextran ﬂuorescent signals that crossed the cells that were cultured without DEX used as
C. DEX treatment enhances TJ formation in 16HBE cells. 16HBE cells were cultured with or
cadherin (upper) and ZO-1 (lower).speciﬁc binding for 10 min at room temperature. Cells were
washed again with PBS, and then reacted with an anti-human E-
cadherin rabbit monoclonal antibody (Cell Signaling Technology,
Beverly, MA, USA) and an anti-human ZO-1 mouse monoclonal
antibody (Zymed Laboratories, Inc., San Francisco, CA, USA) used as
primary antibodies. As secondary antibodies, anti-mouse IgG Alexa
488,594, and anti-rabbit IgG Alexa 488,594 (Life Technologies)
were used. Staining intensity was assessed using a laser scanning
confocal FV1000 microscope (Olympus, Tokyo, Japan) with iden-
tical settings used for all conditions.
Western blotting
Stimulated cells were washed with PBS and proteins were
extracted using lysis buffer that included RIPA buffer (25 mM
TriseHCl, 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate,
and 0.1% SDS), 100 mM PMSF, 10 mg/ml of aprotinin, and 1M
dithiothreitol (DTT). Cell lysates were centrifuged for 10 min at
20817  g. The samples were then boiled, separated by 10% SDS
polyacrylamide gel electrophoresis, and transferred to an
Immobilin-P membrane (Millipore Corp.). The membrane was
incubated with an anti-human E-cadherin rabbit polyclonalects on TER development in 16HBE cells. Cells were seeded on Transwell inserts and
vs. cells cultured without DEX. B. 16HBE cell monolayers permeability to FITC-dextran.
tensity in the lower chamber was measured and compared with the amount of FITC-
a control. Results are means ± SDs (n ¼ 3); *P < 0.05 vs. cells cultured without DEX.
without DEX for 3 days and were then immunostained with antibodies speciﬁc for E-
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mouse monoclonal antibody (Zymed Laboratories) used as primary
antibodies to assess junctional proteins' expression. An appropriate
secondary horseradish peroxidase-conjugated antibody was also
used. Western blots were visualized using an enhanced chem-
iluminescence system (GE Healthcare, Little Chalfont, UK). Bands
on Western blots were quantiﬁed using Image J software and
staining intensity was determined as a percentage of the control.
Statistical analysis
Results are given as means ± standard deviations (SDs). Results
for different experimental groupswere compared using Student's t-
tests. P < 0.05 was considered signiﬁcant. Statistical analyses were
performed using GraphPad Prism Software (La Jolla, CA, USA). To
determine P-values for pathway analysis, we used Fisher's exact
test to estimate how many molecules were non-coincidentally
included in the list of our gene data as compared with molecules
included in the respective pathways. P < 0.05 was considered
signiﬁcant.Fig. 2. Global gene expression proﬁles to identify steroid-inducible genes involved in enhan
iexpressions. Expression proﬁles were normalized to control levels (day 0 of culture witho
efﬁcient of variation). Fold-change analysis was performed using a cut-off of 1.5, assumed
identiﬁed. B. Heat map illustrating differential gene mRNA expression patterns for cells cul
expressed above the average are shown in red, below the average in blue, and at the averaResults
Steroid treatment enhances airway epithelial barrier integrity
We measured TER and FITC-dextran permeability for 16HBE
cells to conﬁrm that dexamethasone (DEX) treatment had
enhanced airway epithelial barrier integrity. Compared to cells
without DEX treatment, TER was signiﬁcantly increased from day 1
to day 3 in cells that were treated with DEX (Fig. 1A). FITC-dextran
permeability was signiﬁcantly reduced in cells treated with DEX as
compared to cells not treated with DEX (Fig. 1B). During DEX
treatment, cells did not proliferate and their viability was not
affected by DEX treatment as determined by Trypan blue exclusion
(data not shown).
Next, to evaluate DEX effects on airway epithelial barrier for-
mation and enhancement, we assessed for any morphological
changes in AJs and TJs by confocal microscopy. We evaluated the
distributions of ZO-1 and E-cadherin in cells with and without DEX
treatment. In sites of epithelial cellecell adhesions, ZO-1, and E-
cadherin were strongly expressed in cell monolayers after DEXcing airway epithelial barrier integrity. A. Microarray data analysis to identify steroid-
ut DEX). Data were ﬁrst ﬁltered by percentiles (20e100%) and CV of <50.0% (CV: co-
as signiﬁcant. A total of 16 up-regulated genes and ﬁve down-regulated genes were
tured with or without DEX for 3 days and a control. Cluster plot. Probe sets that were
ge in yellow.
Fig. 3. Validation of expression data for steroid-inducible genes by real-time RT-PCR. A. Expression levels of up-regulated genes. B. Expression levels of down-regulated genes.
Expression levels in all PCR samples were normalized against GAPDH mRNA, used as a housekeeping gene. Normalized intensity equals the fold-change relative to that of day 0 of
culture without DEX.
Y. Shintani et al. / Allergology International 64 (2015) S54eS63S58
Y. Shintani et al. / Allergology International 64 (2015) S54eS63 S59treatment as compared with cells without DEX treatment (Fig. 1C).
Thus, this conﬁrmed that DEX treatment had enhanced airway
epithelial barrier integrity.Global gene expression analysis using DNA microarrays
Next, we assessed global gene expression proﬁles to identify
steroid inducible genes related to the formation and enhancement
of airway epithelial barrier integrity. We extracted total RNA from
epithelial cells that had been cultured with or without DEX at day
0 and day 3 and used these for microarray analysis. Expression
proﬁles were normalized to the control (day 0 of culture without
DEX). We performed a fold-change analysis using a cut-off value of
a 1.5-fold increase.
First, 9,203 probe sets were identiﬁed (Fig. 2A, left). These data
were analyzed for signiﬁcant variations between day 0 and day 3 of
culture without DEX. These genes were ﬁltered to select those
genes whose expressions were either up-regulated (219 genes) or
down-regulated (112 genes) (Fig. 2A, middle) and further ﬁltered to
select those genes whose expressions were either up-regulated (16
genes) or down-regulated (ﬁve genes) after DEX treatment (Fig. 2A,
right). We identiﬁed 16 up-regulated genes and ﬁve down-
regulated genes as steroid-inducible genes that were involved inFig. 4. Top 19 canonical pathways associated with the formation and enhancement of airw
entially expressed in cells cultured for 3 days with DEX vs. cells cultured for 3 days without D
calculated for each function on the x-axis, with increasing expression indicated by bar hei
information regarding how many “false positives” (i.e., functions falsely identiﬁed as signiﬁthe formation and enhancement of airway epithelial barrier
integrity.
Next, we used heat map analysis to determine differential gene
mRNA expression patterns for three conditions: cells cultured with
and without DEX for 3 days and a control. Because the errors be-
tween samples were less in the heat map, the 21 DEX-induced up-
and down-regulated genes we identiﬁed by microarray analysis
might have been involved in the formation and enhancement of
airway epithelial barrier integrity (Fig. 2B).
Validation of steroid-inducible genes expression
We next validated the expressions of steroid-inducible genes
that were identiﬁed bymicroarray analysis using real-time PCR.We
conﬁrmed that the expressions of ﬁve up-regulated (Fig. 3A) and
down-regulated (Fig. 3B) genes were increased and decreased in
our DNA microarray analysis.
Pathway analysis
Because the 21 genes we identiﬁed had not been previously
reported to be associated with airway epithelial barrier, we next
performed pathway analysis using IPA software (Ingenuity Systems
Inc.) to identify those pathways that were most likely involved inay epithelial barrier function by DEX. Pathway analysis of gene sets that were differ-
EX or vs. control cells. Signiﬁcance is expressed as the negative exponent of the P-value
ght. Functional categories are represented on the y-axis. Threshold P-values provided
cant) that we would maximally expect among the signiﬁcant functions.
Table 1
Genes that are up- or down-regulated by steroid in Nrf2 pathway.
Symbol Entrez gene name Fold
change
Location Type(s)
AOX1 Aldehyde oxidase 1 4.713 Cytoplasm Enzyme
EPHX1 Epoxide hydrolase 1, microsomal
(xenobiotic)
1.174 Cytoplasm Peptidase
FTL Ferritin, light polypeptide 1.108 Cytoplasm Enzyme
NQO1 NAD(P)H dehydrogenase, quinone 1 1.091 Cytoplasm Enzyme
Y. Shintani et al. / Allergology International 64 (2015) S54eS63S60the formation and enhancement of airway epithelial barrier
integrity. The top canonical pathway was the nuclear factor
erythroid 2-related factor 2 (Nrf2)-mediated oxidative stress
response pathway (Fig. 4). The Nrf2 pathway included 192 total
genes in IPA software, of which four genes were detected in our
data. The only up-regulated gene was that for aldehyde oxidase 1
(AOX1) (Table 1).
Nrf2 is involved in enhancing airway epithelial barrier integrity
To determine whether Nrf2 was involved in enhancing airway
epithelial barrier integrity even if Nrf2 was not up-regulated by
DEX treatment, we transfected Nrf2 speciﬁc siRNA into 16HBE cells
and measured these cells' TER and paracellular permeability. TER
was signiﬁcantly reduced in Nrf2 knockdown cells as compared
with cells transfected with control siRNA (Fig. 5A). FITC-dextran
permeability was also signiﬁcantly increased in Nrf2 knockdown
cells as compared with cells transfected with control siRNA
(Fig. 5B). These data suggested that Nrf2 was involved in regulating
airway epithelial barrier integrity.Fig. 5. Nrf2 knockdown effects on TER development and TJ organization. A. Nrf2 knockdown
siRNAs. After 24 h, cells were cultured with or without DEX for 2 days. TER was monitored
monolayers permeability to FITC-dextran. After measuring TER, FITC-dextran (4 kDa) was ad
for 1 h. Fluorescence intensity in the lower chamber was measured and compared to the am
DEX and transfected with control or Nrf2-speciﬁc siRNAs. Results are means ± SDs (n ¼ 3);
expression in Nrf2 knockdown cells. 16HBE cells were subjected to immunocytochemistry
analysis for E-cadherin and ZO-1 proteins in 16HBE cells after treatment with Nrf2 siRN
normalized by b-actin. Western blots were prepared for three independent experiments. RNext, we examined the accumulation of AJ and TJ proteins in
epithelial cellecell junctions by confocal microscopy to evaluate
the role of Nrf2 for airway epithelial barrier formation and
enhancement using cells that were transfected with Nrf2-speciﬁc
siRNA or control siRNA and cultured with DEX. At sites of
cellecell junctions, E-cadherin and ZO-1were strongly expressed in
control cell monolayers, whereas their expressions were reduced in
Nrf2 knockdown cell monolayers (Fig. 5C). To conﬁrm that these
proteins' expressions were not increased or decreased in whole
cells including cytosol, we performed Western blot analysis to
assess total E-cadherin and ZO-1 protein expressions. E-cadherin
and ZO-1 protein expression did not change in 16HBE cells that
were transfectedwith Nrf2 siRNA or control siRNA (Fig. 5D, E). Thus,
Nrf2 knockdown had suppressed the accumulation of TJ and AJ
proteins to reduce the formation and enhancement of airway
epithelial barrier integrity induced by DEX treatment.Nrf2/AOX1 pathways is involved in airway epithelial barrier
integrity
Next, we explored for downstreammolecules of Nrf2 that might
be associated with enhanced airway epithelial barrier integrity
induced by DEX treatment. Based on our pathway analysis data,
only AOX1 gene expression in the Nrf2 pathway was increased by
DEX (Table 1). Up-regulated AOX1 mRNA expression induced by
DEX was signiﬁcantly reduced in Nrf2 knockdown cells as
compared with that in cells transfected with control siRNA
(Fig. 6A), which suggested that AOX1 was a downstream molecule
of Nrf2. Then, we assessed whether AOX1 actually participated in
enhancing airway barrier integrity.effects on TER development. 16HBE cells were transfected with control or Nrf2-speciﬁc
for 2 days. Results are means ± SDs (n ¼ 3); *P < 0.05 vs. control siRNA. B. 16HBE cell
ded to the upper chamber of a Transwell insert and allowed to cross the cell monolayer
ount of FITC-dextran ﬂuorescent signals that crossed the cells cultured with or without
*P < 0.05 vs. control siRNA. C. Immunocytochemistry analysis of E-cadherin and ZO-1
with antibodies speciﬁc for E-cadherin (top) and ZO-1 (bottom). D. Western blotting
A. E. Densitometric analysis of E-cadherin and ZO-1 is represented as fold change,
esults from one typical experiment are shown.
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cultured with DEX, after which we measured TER and evaluated
paracellular permeability using FITC-dextran. TER was signiﬁcantly
reduced in AOX1 knockdown cells as compared to cells that were
transfected with control siRNA (Fig. 6B). FITC-dextran permeability
was also signiﬁcantly increased in AOX1 knockdown cells as
compared with cells transfected with control siRNA (Fig. 6C).Fig. 6. Effects of suppressing the expression of oxidative stress-responsive genes by
Nrf2 gene silencing. A. 16HBE cells were transfected with control or Nrf2-speciﬁc
siRNAs. After 72 h, RNA was extracted. The differences in AOX1 gene expression
levels were compared for cells with or without DEX treatment using real-time PCR.
mRNA expression levels in all PCR samples were normalized against GAPDH mRNA,
used as a housekeeping gene. Normalized intensity equals the fold-change relative to
cells transfected with control siRNA and without DEX treatment. Results are
means ± SDs (n ¼ 3); *P < 0.05 vs. control siRNA. B. AOX1 knockdown effects on TER
development. 16HBE cells were transfected with control or AOX1-speciﬁc siRNAs. After
24 h, cells were cultured with or without DEX for 2 days. TER was monitored for 2 days.
Results are means ± SDs (n ¼ 3); *P < 0.05 vs. control siRNA. C. AOX1 knockdown
effects on paracellular permeability of 16HBE cell monolayers to FITC-dextran. After
measuring TER, FITC-dextran (4 kDa) was added to the upper chamber of a Transwell
insert and allowed to cross a cell monolayer for 1 h. Fluorescence intensity in the lower
chamber was measured and compared to the amount of FITC-dextran ﬂuorescent
signals that crossed the cells cultured with or without DEX and transfected with
control or AOX1-speciﬁc siRNAs. Results are means ± SDs (n ¼ 3); *P < 0.05 vs. control
siRNA.Together, these data suggested that the Nrf2/AOX1 pathway was
involved in the formation and enhancement of airway epithelial
barrier integrity.
Discussion
It was recently proposed that the susceptibility to reduced
airway epithelial barrier integrity may be involved in the patho-
genesis and development of bronchial asthma.21 We previously
reported that the promoting effect of phosphorylation to EGFRs by
DEX was involved in enhancing airway epithelial barrier integrity.8
However, the mechanism bywhich DEX enhances airway epithelial
barrier integrity is not well understood.
In this study, we performed a global gene expression analysis to
determine the mechanism by which DEX could enhance airway
epithelial barrier integrity and to identify steroid-inducible genes
that were involved in enhancing airway epithelial barrier integrity.
Based on this analysis, we identiﬁed 16 genes as steroid-inducible
genes. However, there is no report that the top ﬁve up-regulated
genes, including BIRC3, KRT6A, AOX1, LOX, and NNMT, alone
are involved in the airway epithelial barrier integrity. Thus, we
performed a pathway analysis to identify the signaling pathways
that were upstream or downstream of these genes with altered
DEX-induced expression. Based on our pathway analysis, Nrf2-
mediated oxidative stress response was the most important
canonical pathway involved in enhancing airway epithelial barrier
integrity by steroid treatment. We conﬁrmed that Nrf2 mRNA
expression after DEX treatment was not increased using real-time
PCR (data not shown).
Nrf2 is a transcription factor that has an antioxidant effect and
has a basic leucine zipper (b-Zip) structure.22 Nrf2 binds to Kelch-
like ECH-associated protein1 (Keap1) under non-oxidative stress
conditions. Nrf2 is inhibited its activation when it is degraded by
the proteasome.22 When the cells are exposed to oxidative stress,
Nrf2 binding site of Keap1 is saturated and the newly synthesized
Nrf2 migrates into the nucleus.23 Then, Nrf2 binds to an electro-
phile/antioxidant responsive element (EpRE/ARE) that is in the
expression control region of a target gene, Nrf2 can enhance the
expression of antioxidant genes.24 Our data consistent with this
mechanism that Nrf2 pathway may be activated by DEX without
increasing gene expression of Nrf2. Reactive oxygen species levels
that are increased by various environmental factors induce oxida-
tive stress, which has been shown to one component in the path-
ogenesis of asthma.25 It has been shown that human
immunodeﬁciency virus (HIV)-1-related proteins inhibit Nrf2-
mediated antioxidant defenses and thereby disrupt the normally
tight alveolar epithelial barrier.26 We hypothesized that a steroid-
activated Nrf2 would regulate the expression of antioxidant mol-
ecules and, subsequently, epithelial barrier integrity. Unexpectedly,
the gene expressions for antioxidant molecules, such as UGT1a6
and NQO1, were decreased in cells that were cultured with DEX
based on our microarray analysis data (data not shown). This sug-
gested that steroid-enhanced airway epithelial barrier integrity
might be regulated by an antioxidant effect independent pathway.
Because Nrf2 knockdown attenuated airway epithelial barrier
integrity, Nrf2 might still be involved in airway epithelial barrier
integrity even if Nrf2 expression was not up-regulated by DEX.
Next, we focused on the Nrf2 pathway to determine the role of
Nrf2 for airway epithelial barrier integrity. In our pathway analysis,
four genes were detected in the Nrf2 pathway. Only AOX1 gene
expression was increased during formation and enhancement of
airway epithelial barrier integrity. AOX1 is a molybdenum ﬂavin
enzyme, which is particularly strongly expressed in the liver and
catalyzes the oxidation of various aldehyde compounds with broad
substrate speciﬁcity.27 AOX1 is important as a xenobiotic
Fig. 7. Schematic diagram showing the relationship between the Nrf2 pathway and airway epithelial barrier integrity. Scheme for a possible connection with Nrf2 and molecules
involved in airway epithelial barrier integrity.
Y. Shintani et al. / Allergology International 64 (2015) S54eS63S62metabolizing enzyme that affects the metabolism of anticancer
drugs, immunosuppressive agents, and antiviral agents.28
The AOX1 gene expression level after steroid treatment was
signiﬁcantly reduced in those cells that were transfected with Nrf2
siRNA as compared with control cells, which suggested that AOX1
was one of the downstream molecules regulated by Nrf2. We
measured TER and membrane permeability for cells that were
transfected with AOX1-speciﬁc siRNA to determine whether AOX1
was involved in the formation and enhancement of airway
epithelial barrier integrity after DEX treatment. This showed that
AOX1 was involved in the formation and enhancement of airway
epithelial barrier function by steroids in the downstream pathway
of Nrf2.
Nrf2 enhances the expression of target genes after it trans-
locates into the cell nucleus and binds to an ARE. Maeda et al. re-
ported that an ARE was in the 50 upstream region of the AOX1 gene
and that AOX1 gene expression was enhanced when Nrf2 bound to
this ARE.29 It is possible that Nrf2 binding to this ARE in the AOX1
gene is involved in the formation and enhancement of airway
epithelial barrier function. Further studies will be needed to
elucidate the mechanism underlying the formation and enhance-
ment of airway epithelial barrier integrity via the Nrf2/AOX1
pathway.
Sulforaphane is a naturally occurring chemical that is found in
plants, particularly in large amounts in broccoli and sprouts,30 and
exhibits antioxidant activity by activating Nrf2.28 Sulforaphane
suppressed TH2 responses when it was administered intraperito-
neally along with ovalbumin in an animal model of asthma.31
Sulforaphane, an Nrf2 activator, has been reported to enhance the
epithelial barrier in vitro.32 Indeed, we conﬁrmed that sulforaphane
enhanced airway epithelial barrier integrity in our model system
(data not shown). Nrf2 activators, such as sulforaphane, might have
potential for suppressing asthma pathogenesis by activating the
Nrf2 pathway and enhancing barrier integrity.
In conclusion, the Nrf2/AOX1 pathway that we identiﬁed in
airway epithelial cells might be a new therapeutic target for
asthma patients by enhancing airway epithelial barrier integrity
(Fig. 7). Clinically, the use of an ICS has dramatically improved
the long-term control of bronchial asthma4; however, there are
patients with severe asthma who are steroid-resistant.6 It is
possible that Nrf2 activators might be a new treatment strategyfor asthma by enhancing airway epithelial barrier integrity in
place of an ICS.Acknowledgments
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